Business Insider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Goldman Sachs wants to know how many employees have been vaccinated, per a memo seen by the NYT.Goldman said it"strongly encourages" getting a shot, but said it's a"personal" choice.Goldman Sachs is keen to know how many of its US employees have been vaccinated as staff return to offices.
The bank asked its US staff to report whether they've got the COVID-19 shot by 12 p.m. Thursday, according to an internal memo viewed by The New York Times'The memo was sent earlier this week to bankers who had not yet reported their vaccination status, The Times said. "Registering your vaccination status allows us to plan for a safer return to the office for all of our people as we continue to abide by local public health measures," the memo said, per the Times.
It wasn't clear if report vaccination status was mandatory. Goldman Sachs said in the memo that it"strongly encourages" getting vaccinated, but said the choice"is a personal one," per the Times.The bank told staff in the Manhattan office in May that they didn't have to wear masks if they reported their vaccination — this now applies to all US employees, The Times reported.
Workers will need to record the date they got the COVID-19 vaccine and which shot they received, The Times said. They don't need to show proof, the memo said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Exclusive: Goldman Sachs CEO David Solomon Encourages Small Businesses To ‘Stay The Course’ As The Economy AcceleratesGoldman Sachs Chairman & CEO David Solomon on small business optimism and continued challenges as the economy accelerates post-pandemic.
Read more »
Colbert Jabs Anti-Vaxxers With The Truth About Their Latest Wild ConspiracyA wild theory about COVID-19 shots got the treatment from 'The Late Show' comedian.
Read more »
Ocugen to file for full U.S. approval of COVID-19 shot instead of EUAOcugen Inc (OCGN.O) said on Thursday it would no longer pursue an emergency use authorization for its COVID-19 vaccine candidate, Covaxin, and would instead aim to file for a full U.S. approval of the shot.
Read more »